On the horizon: pathways for drug development in Alzheimer's disease.
Hake
Ann Marie
AM
Department of Neurology, Indiana University School of Medicine, 541 Clinical Drive, Suite 299, Indianapolis, IN 46202, USA. ahake@iupui.edu
Farlow
Martin R
MR
D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical / Q000639:trends; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005544:Forecasting; D006801:Humans; D018697:Nootropic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002800:Cholinesterase Inhibitors; D015507:Drugs, Investigational; D018697:Nootropic Agents